NCT07431086

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, Tolerability, and Efficacy of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity in the US

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study will test how safe and effective the study drug works compared to placebo in people who are overweight or obese but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much the study drug is in the blood at different times * How well the study drug works * If your body makes antibodies to the study drug, as this may cause the study drug to not work as well

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	Olatorepatide	Administered per the protocol
DRUG	Placebo	Administered per the protocol

Timeline

• Start date: 2026-03-16
• Primary completion: 2026-11-13
• Completion: 2026-12-18
• First posted: 2026-02-24
• Last updated: 2026-03-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study